Pegadria 20 Injection 10 ml is an anti-cancer medicine used in the treatment of cancer. Cancer is a disease where the cells grow abnormally and divide uncontrollably. Pegadria 20 Injection 10 ml is primarily used as adjuvant chemotherapy in women with axillary lymph nodes with involvement resection of breast cancer (abnormal growth in the cells of the breast). It is also used to treat neuroblastoma (cancer that starts in nerve cells and primarily affects children) and Wilms' tumor (a form of kidney cancer that affects children).

Pegadria 20 Injection 10 ml contains Doxorubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, destroying DNA and RNA synthesis.

Pegadria 20 Injection 10 ml may cause certain side effects such as nausea, headache, abdominal pain, loss of appetite, vomiting, dizziness, mouth sores, tiredness, back pain, red discoloration of urine, diarrhea, and pain at the site of injection. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. A trained healthcare doctor will administer Pegadria 20 Injection 10 ml. So, do not self-administer. Your doctor will decide the dose of the medicine based on your health condition.

Pegadria 20 Injection 10 ml should be avoided if you are allergic to it or any other components of this medicine. It is contraindicated in patients having severe myocardial insufficiency, a recent history of myocardial infarction (MI), severe persistent drug-induced myelosuppression, and severe liver disease. Hence, if you have any such conditions, inform your doctor. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any CYP3A4 or CYP2D6 inducers medication, as it can cause adverse effects. Pegadria 20 Injection 10 ml is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand.

Pegadria 20 Injection 10 ml contains Doxorubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, thereby destroying the DNA and RNA synthesis. Pegadria 20 Injection 10 ml is also used in the treatment of acute lymphoblastic leukaemia, acute myeloblastic leukaemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumour, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma

• Nausea
• Abdominal pain
• Vomiting
• Dizziness
• Back pain
• Pain at the site of injection
• Red discolouration of urine
• Loss of appetite
• Mouth sores
• Tiredness
• Weight gain

Pegadria 20 Injection 10 ml should be avoided if you are allergic to it. It is contraindicated in patients having severe myocardial insufficiency, a recent history of myocardial infarction (MI), severe persistent drug-induced myelosuppression and severe liver disease. Hence avoid using this medicine under such conditions. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any CYP3A4 or CYP2D6 inducers medication, as it can cause serious adverse effects. Pegadria 20 Injection 10 ml is known to cause embryo-fetal toxicity. Hence it is contraindicated in pregnant or breastfeeding women. Do not stop receiving Pegadria 20 Injection 10 ml without a doctor’s advice, as it can cause serious health conditions. Pegadria 20 Injection 10 ml is known to cause secondary malignancies, tissue necrosis, cardiomyopathy and septic shock in some patients. Hence careful monitoring of the patient is needed while receiving the medicine.

Drug-Drug Interactions: Pegadria 20 Injection 10 ml may interact with CYP3A4 inducers (phenytoin, phenobarbital, rifampicin), CYP3A4 inhibitors (clarithromycin, voriconazole, cyclosporine, chloramphenicol), CYP2D6 inhibitors (bupropion, fluoxetine, paroxetine), CYP2D6 inducers (dexamethasone, corticosterone, haloperidol).

Drug-Food Interactions: Avoid smoking and alcohol consumption.

Drug-Disease Interactions: Inform your doctor if you have cardiac problems, liver or kidney disease.

• PHENYTOIN
• PHENOBARBITAL
• RIFAMPICIN
• CLARITHROMYCIN
• VORICONAZOLE
• CYCLOSPORIN
• BUPROPION
• PAROXETINE
• FLUOXETINE
• DEXAMETHASONE
• HALOPERIDOL

• Meditation and yoga have been proven very effective in helping cancer patients maintain a healthy attitude and body.
• Eat more lean meats, healthy fats, fruits, vegetables, and whole-grain foods to give you more energy. 
• Stay hydrated by drinking plenty of water, as dehydration is often seen in cancers.
• Taking a stroll in the garden or spending 30 minutes of your time doing some light physical activity can be very useful. However, do not over-exert yourself if you feel too tired. 
• Avoid smoking and alcohol consumption.

• Avoid intercourse while on treatment with Pegadria 20 Injection 10 ml.
• Regular complete blood count monitoring is advised.  Also, monitoring of liver function is important while receiving Pegadria 20 Injection 10 ml.

• According to postmarketing reports, juvenile children receiving doxorubicin hydrochloride are at risk of developing late cardiovascular dysfunction. Risk factors include early age during treatment (particularly five years), large cumulative dosages, and receipt of multimodal modality therapy. All pediatric patients who have received doxorubicin hydrochloride should undergo long-term cardiovascular monitoring.

Breast Cancer: Breast cancer is a type of cancer with abnormal growth in the cells of the breast. There are different kinds of breast cancer, such as cancer occurring in lobules (glands that produce milk), ducts of the breast (the pathway that brings milk from glands to the nipple), and in the fatty tissue or the fibrous connective tissue within the breast. Symptoms of breast cancer include a lump in the breast, breast pain, redness, swelling, nipple discharge other than breast milk, bloody discharge, a lump or swelling under the arm, unexplained change in shape, size or appearance of the breast, peeling, flaking or scaling of the skin. 

Lymphoma: Lymphoma is a wide word for cancer that develops in lymph system cells. Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) are the two most common kinds. Hodgkin lymphoma is frequently curable.